Avidity Biosciences, Inc. (NASDAQ: RNA) related to its sale to Novartis AG. Under the terms of the proposed transaction, Avidity shareholders will receive $72.00 per share in cash.
Avidity Biosciences, Inc. (NASDAQ: RNA) related to its sale to Novartis AG. Under the terms of the proposed transaction, Avidity shareholders will receive $72.00 per share in cash.